Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has trended somewhat positive on Friday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regulus Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.7427718656667 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.
A number of analysts have recently issued reports on the stock. Wedbush reiterated an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a research note on Monday, August 7th. Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. Finally, Chardan Capital lowered shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. Regulus Therapeutics presently has a consensus rating of “Hold” and an average target price of $3.67.
WARNING: “Regulus Therapeutics (RGLS) Earning Somewhat Positive News Coverage, Report Shows” was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.truebluetribune.com/2017/10/13/regulus-therapeutics-rgls-earning-somewhat-positive-news-coverage-report-shows.html.
In other news, Director William H. Rastetter bought 274,725 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was acquired at an average cost of $0.91 per share, for a total transaction of $249,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joseph P. Hagan bought 219,780 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, with a total value of $199,999.80. Following the completion of the purchase, the insider now directly owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Insiders purchased 549,450 shares of company stock valued at $500,000 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.